{
    "code": 0,
    "data": [
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Earnings Call Transcript",
            "news_id": "b53ced32-741d-4dd7-b758-dc622d6fa858",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb27f929-a2a1-4ecf-a6b8-4c3c9750cf12.pdf",
            "news_date": "2026-02-05 11:05:30",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pls find enclosed Audio recording of Earnings call conducted on 30th January 2026",
            "news_id": "9d442ca3-826e-4f75-a7fe-fa04deb228c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5062da09-f6b0-4e57-8d61-dd6a1fe77061.pdf",
            "news_date": "2026-01-30 17:44:28",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For Quarter Ended 31St December 2025.",
            "news_body": "Pls find enclosed results for quarter ended 31st December 2025.",
            "news_id": "f0718880-bc9a-447b-b16e-6ab2b8c3de1d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62f9a571-200b-4472-bb3f-3a7a1cd649cc.pdf",
            "news_date": "2026-01-30 15:03:57",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Written Transcript of Earnings Call",
            "news_id": "89281a08-e235-42f3-a0ae-808795c52647",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e375f416-b0e8-4573-987d-98acbe50ee81.pdf",
            "news_date": "2025-11-06 08:53:09",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 3rd November 2025",
            "news_id": "63bedeb9-3de0-446b-a942-1d3174f2d050",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3e8b4fc-86ad-4566-b08b-d98d4f7cb04e.pdf",
            "news_date": "2025-11-03 16:37:02",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025",
            "news_body": "PFA Unaudited Financial Results for 30.09.2025",
            "news_id": "5f60c872-66d3-4432-9ff4-f69eefd51b82",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3ae3f4a-9a49-4da7-97c8-29fdbdce241d.pdf",
            "news_date": "2025-11-03 13:25:33",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Written Transcript of Earnings Call held on 28th July 2025.",
            "news_id": "ad1e0039-0ecb-4ce1-acc3-5fc334700cb2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f4616fe-ef4e-4b4e-847a-c120c78b6669.pdf",
            "news_date": "2025-07-31 11:06:28",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter Ended 30.06.2025",
            "news_body": "PFA Unaudited Financial Results for quarter ended 30.06.2025.",
            "news_id": "75942d6e-e128-48ee-9775-4048733c338f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cf818b5-e94c-4440-983a-30cdf70e514c.pdf",
            "news_date": "2025-07-28 14:59:53",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Earnings Call Transcript",
            "news_id": "cfa518fc-6bb5-49a5-bd26-2302e35e1e62",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5e6cc3b-3f5e-4dcf-8ad2-0eed53ec508b.pdf",
            "news_date": "2025-05-05 15:05:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 30th April 2025",
            "news_id": "23f46fc5-cc44-4515-a80d-dc789171e19d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d46786a7-3457-4077-8803-ef79b49e5f0b.pdf",
            "news_date": "2025-04-30 18:20:42",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "PFA Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2025 Pursuant To Regulation 33 Of SEBI (LODR).",
            "news_body": "PFA Audited Results",
            "news_id": "f9b1e6a0-d127-4db0-abb8-3c96a6e36556",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c209dff-01ae-4656-8d9d-b3db7504ee8b.pdf",
            "news_date": "2025-04-30 15:23:35",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Written Transcript of Earnings Call conducted on 30th January 2025.",
            "news_id": "e68ca37c-4721-4f47-955d-6e22432becd9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=935d8784-73b0-47a4-acb3-00e8f4ebac68.pdf",
            "news_date": "2025-02-03 16:23:32",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Nine Months Ended 31St December 2024.",
            "news_body": "PFA Results of 31st Dec 2024.",
            "news_id": "29fd1e5e-ab37-4f20-b4e8-338e25da30b5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c389b762-9030-46e2-9785-2ce8f0dba0dc.pdf",
            "news_date": "2025-01-30 15:35:09",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Earning Call Transcript",
            "news_id": "58ea631a-8ea3-4f92-ba91-680286b703fc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca0017a7-cb7c-4b0e-865e-e09358d8b46d.pdf",
            "news_date": "2024-10-30 17:55:47",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audior Recording Link of the Investor Call Meeting",
            "news_id": "8899d06d-c6d6-4b40-a164-bacdcb58250d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a82ac20-ddeb-41ba-93d8-0f472fde7285.pdf",
            "news_date": "2024-10-28 18:31:25",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Half Year Ended 30.09.2024.",
            "news_body": "PFA Results of HI FY25",
            "news_id": "b2a632dc-984f-4dcd-b4ce-b086036b6d48",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf9aa7db-5f4d-4190-af0d-0cf157f0d3aa.pdf",
            "news_date": "2024-10-28 15:51:28",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call conducted on 30th July 2024",
            "news_id": "03ecef83-2a3b-465e-a60c-36050aae8c04",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abb0b970-f53a-4007-ac6a-cd1d1f4a2a3b.pdf",
            "news_date": "2024-08-02 17:39:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 30th July 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link:   https://ajantapharma.com//images/EarningsAudio-Q1-FY2025.mp3",
            "news_id": "a20a6d0f-c30f-4a25-bbc0-76a5c9dbc0e6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ea3a5fe-d177-4412-902d-a197f348d783.pdf",
            "news_date": "2024-07-30 18:49:42",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting For Approving Unaudited Financial Results For Quarter Ended 30.06.2024",
            "news_body": "PFA outcome of Board Meeting",
            "news_id": "60bf5432-0864-4cef-8182-bf6a452e8fd6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0207d4a4-925e-4275-8915-f1c7e21b471c.pdf",
            "news_date": "2024-07-30 15:01:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call conducted on 2nd May 2024.",
            "news_id": "33ce1bf6-6322-4288-987f-134fa249b008",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a62da3c-8611-46f8-ad58-e259f136d1a5.pdf",
            "news_date": "2024-05-08 14:03:43",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 2nd May 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link:   https://ajantapharma.com//images/EarningsAudio-Q4-FY2024.mp3",
            "news_id": "829281aa-8fe6-43d2-8e46-0e8b6dbd9feb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81a65223-88bd-453b-9cc4-a08efdc1de73.pdf",
            "news_date": "2024-05-02 20:33:54",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results-Financial Results For 03,31,2024",
            "news_body": "Outcome of Board Meeting",
            "news_id": "e954c539-68e8-4de0-b25a-9670efed8b42",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87b56f4f-8d55-42ce-9845-5f889c3937d8.pdf",
            "news_date": "2024-05-02 16:39:45",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call conducted on 31st January 2024.",
            "news_id": "526c8c56-818d-4c13-aa91-a4ef01b88e76",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a47b89b5-e835-47c5-b686-e6d2b61e1fab.pdf",
            "news_date": "2024-02-05 16:49:46",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st January 2024 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:   https://ajantapharma.com//images/EarningsAudio-Q3FY2024.mp3",
            "news_id": "a7d70196-7ff7-4da4-b573-9063a9e5df6c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43de6454-fe17-4ba7-a7bc-63b1e4b77b5e.pdf",
            "news_date": "2024-01-31 19:50:17",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter And Nine Months Ended 31St December 2023",
            "news_body": "Results for Dec 2023",
            "news_id": "aee21e94-2a00-43ce-b533-df38b5fcc931",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=526e6d11-fa74-448e-9896-ce13cdc34d86.pdf",
            "news_date": "2024-01-31 16:12:24",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith Written Transcript of Earnings Call held on 31st October 2023.",
            "news_id": "432cb5a7-cbd4-4ad2-931b-019f6c77ca86",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bd02dde-7d9d-4025-8e5d-610f7b4ec805.pdf",
            "news_date": "2023-11-03 12:15:37",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st October 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EarningsAudio-Q2FY2024.mp3Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "5a5aea31-f53b-455c-b484-c9d8387343a9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a2cd9541-eea3-4bc9-a9c9-546d4e768153.pdf",
            "news_date": "2023-10-31 19:24:55",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Second Quarter And Half Year Ended 30Th September 2023",
            "news_body": "Results for the Second Quarter and Half Year Ended 30th September 2023.",
            "news_id": "8f7ae33d-08b7-43ac-8fb5-82b18bde1058",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2b564d9-f6e1-4bce-9e97-e32da18568e9.pdf",
            "news_date": "2023-10-31 14:15:46",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call held on 27th July 2023.",
            "news_id": "c3558683-9ce4-422c-b31e-49ae55198d01",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b4972d7-306f-4d98-a52b-bdbf9b4f5448.pdf",
            "news_date": "2023-08-02 17:23:45",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 27th July 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EarningsAudioQ1-2023-24.mp3Written transcript of the same will be submitted in due course.",
            "news_id": "7bd194ca-90af-48f5-84e8-163c84b31e23",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d59261e-c947-4030-bc26-a7398484aeab.pdf",
            "news_date": "2023-07-27 19:04:38",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Quarter Ended 30Th June 2023",
            "news_body": "Enclosed Financial results for quarter ended 30th June 2023.",
            "news_id": "15e34e77-4ff0-48f7-ac1b-cec6f2f4b5aa",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c944b568-5374-42c4-a4ff-6fbea16322c6.pdf",
            "news_date": "2023-07-27 15:59:56",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 5th May 2023 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 5th May 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallTranscriptQ4(Jan-Mar)2022-23.pdf.",
            "news_id": "601944a6-4ae1-4761-9215-4e3b99db0284",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1e28fab-5ec4-4504-b771-e71dcd96f458.pdf",
            "news_date": "2023-05-11 12:09:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 5th May 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EAC-Q4-(Jan-Mar)-2022-23.mp3Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "f4b3ddae-b813-4cc8-9d76-586e3642b57c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9b2356a-1aac-4ede-a500-b60e4f4b05d5.pdf",
            "news_date": "2023-05-05 20:12:37",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2023",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith following:<BR> 1. Press Release;<BR> 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion;<BR> 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion;<BR> 4. Investor presentation.",
            "news_id": "e271aeaa-4c1a-4cde-8c63-c05f49bb8407",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=186a93f2-85ba-4e2a-9ccd-0a80e5993cfb.pdf",
            "news_date": "2023-05-05 15:46:55",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "We hereby inform that at the Board meeting held on Friday, 5th May 2023, Board has inter-alia approved and taken on record the Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2023.<BR> <BR> Board has also approved amendment in the object clause of Memorandum of Association (MOA) to align the same with regulatory requirements. There is no change in the principal business of the Company. This amendment is subject to approval of the shareholders at the ensuing Annual General Meeting.",
            "news_id": "62b539c5-37a0-47e6-8310-e6893e0d0b4e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=684ad1be-1eda-44f1-a5a5-9f7e093cfc56.pdf",
            "news_date": "2023-05-05 15:40:05",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 2nd February 2023 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EarningsCallTranscriptQ3(Oct-Dec)2022-23.pdf",
            "news_id": "a7673039-cf99-4614-bd78-8fdef98cb28e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42628511-3350-44be-bd69-f28ab239201a.pdf",
            "news_date": "2023-02-13 09:54:05",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallAudioQ3(Oct-Dec)2022-23.mp3",
            "news_id": "363bcf26-42f1-4129-9775-cb2fa6e257dc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c444d28-f0ee-4978-a297-5d2d3e6c56cf.pdf",
            "news_date": "2023-02-02 10:54:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter And Nine Months Ended 31St December 2022",
            "news_body": "Results for the quarter and nine months ended 31st December 2022",
            "news_id": "a43547c7-54a0-4a9d-820c-34bd05f50966",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=334f7dd3-b18a-4803-9fde-cad75ae7b809.pdf",
            "news_date": "2023-02-01 16:09:11",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited<BR> Financial results for the quarter and nine months ended 31st December 2022. Pursuant to Regulation<BR> 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.<BR> <BR> Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,<BR> 2015, we would like to inform that based on the recommendations of Nomination & Remuneration<BR> Committee meeting held today, Board has also approved the re-appointment of Mr. Yogesh Agrawal<BR> as Managing Director and Mr. Rajesh Agrawal as Joint Managing Director for a further period of five<BR> years from 1st April 2023 upto 31st March 2028, subject to approval of members.",
            "news_id": "7ca0566c-ab1f-49be-934c-0bce506395c4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10aa6900-e036-4d3b-8181-fca2fdb301ce.pdf",
            "news_date": "2023-02-01 15:37:37",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 3rd November 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 3rd November 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallTranscriptQ2FY23.pdf .",
            "news_id": "dd0d9168-343a-41ac-8131-2276cd930fc0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5bfe024e-353a-4d31-9fc3-7989ed99f58f.pdf",
            "news_date": "2022-11-10 13:07:44",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 3rd November 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EC-AudioQ2(Jul-Sep)2022-23.mp3",
            "news_id": "5ea88a8c-839b-41c0-8430-41221e82e182",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b25ae24-3a80-441a-80c6-f26dc9c77af2.pdf",
            "news_date": "2022-11-04 10:32:51",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Second Quarter And Half Year Ended 30Th September 2022",
            "news_body": "Results for second quarter and half year ended 30th September 2022",
            "news_id": "18422a82-7935-4532-a31c-58dfa39f1b7b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d811d70-bd4e-4ebd-93bc-17e55fa7b0ee.pdf",
            "news_date": "2022-11-03 15:57:00",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 3rd November 2022, approved the following:<BR> i. Unaudited Consolidated and Standalone Financial Results of the Company for the second quarter and half year ended 30th September 2022;<BR> ii. Payment of interim dividend of Rs. 7/- (350%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2022-23;<BR> iii. Fixed Monday, 14th November 2022 as the Record date for payment of interim dividend. Interim dividend will be paid on or after 24th November 2022.",
            "news_id": "c83d2425-7e1a-46ea-8aa4-ccf5a9f39042",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1cd99034-8a39-4832-9030-f1595e760892.pdf",
            "news_date": "2022-11-03 15:39:53",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 29th July 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed written transcript of the earnings call held on 28th July 2022 at 5.00 p.m.Further, written transcript has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ1(Apr-Jun)2022-23.pdfThis is for your information and records please.",
            "news_id": "e5f6e05c-52d0-4989-a137-57b53e60e5a9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=694ff1ee-1c91-42d0-aeb1-56e94bb44931.pdf",
            "news_date": "2022-08-03 18:35:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 28Th July 2022",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 28th July 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ1(Apr-Jun)2022-23.mp3Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "9883b596-fa12-4ad9-8c22-16d40028760d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2be4010a-e48a-4ba7-9344-9ddcd0c99a35.pdf",
            "news_date": "2022-07-29 10:32:20",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Quarter Ended 30Th June 2022",
            "news_body": "At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2022. Pursuant to Regulation 33 of SEBI LODR Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter ended 30th June 2022;<BR> ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> vi. Investors' presentation.<BR> <BR> Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records.",
            "news_id": "6410cc04-81e6-405c-b4d2-fb710e2b7985",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8be1bdd8-c16f-4c74-9e05-bccdd31f458f.pdf",
            "news_date": "2022-07-28 16:19:10",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter ended 30th June 2022;<BR> ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iii. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> v. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> vi. Investors' presentation.<BR> <BR> Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records.",
            "news_id": "de917ec5-fd60-4fde-a2b0-92f476e0909d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94f7af8b-bd40-4cb1-9233-234a5498dd95.pdf",
            "news_date": "2022-07-28 16:07:06",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 10th May 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsC allTranscriptQ4(Jan-Mar)2021-22.pdf",
            "news_id": "97964789-f4ec-46ab-98ae-72fbc7b5e771",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7dccf0c6-431c-435b-8830-eb737f332061.pdf",
            "news_date": "2022-05-14 13:09:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 10Th May 2022",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 10th May 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link in the attachment.Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "32d139ba-4c85-4427-9582-496301c062c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6bdad93f-0042-47a1-87a4-c7bfdced2147.pdf",
            "news_date": "2022-05-11 10:46:45",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "We hereby inform that at the Board meeting held on Tuesday, 10th May 2022, the Board has interalia:<BR> <BR> a. Approved and taken on record, Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2022;<BR> b. Approved issue of bonus shares in the ratio of 1:2 i.e. One new fully paid-up equity shares of Rs. 2/- each to be issued for every Two equity shares held, subject to approval of shareholders of the Company. Separate disclosure under Regulation 30 is being filed shortly;<BR> c. Recommended re-appointment of M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022) as statutory auditors of the Company for second term of 5 years, from the conclusion of 43rd Annual General Meeting till the conclusion of 48th Annual General Meeting, subject to the approval of the shareholders of the Company.",
            "news_id": "a3414727-9621-4c2d-8af4-d100630ac9c0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6818442d-3b8a-4ffe-b4b9-2d93b2f88704.pdf",
            "news_date": "2022-05-10 14:13:12",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 31st January 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ3(Oct-Dec)2021-22.pdfThis is for your information and records please.",
            "news_id": "3ae13e8d-8931-4c17-b735-ee49e622d9e4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ae34c56-60dc-4710-858a-646de80fce56.pdf",
            "news_date": "2022-02-04 14:26:00",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 31St January 2022",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ3(Oct-Dec)2021-22.mp3",
            "news_id": "86217257-6da2-4fd4-940b-309004df5f4d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ad87c86-7345-49a0-b3cf-2810eed45de9.pdf",
            "news_date": "2022-01-31 19:32:27",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter and nine months ended 31st December 2021;<BR> ii. Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2021;<BR> iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2021;<BR> iv. Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2021;<BR> v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2021;<BR> vi. Investors' presentation.<BR> Kindly note that the meeting of the Board of Directors commenced at 1.45 p.m. and concluded at 3.15 p.m. and take the above on your records.",
            "news_id": "81e7e616-c9ba-4045-850f-77e496d4ea5e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2d591b4-c2d6-45f6-b7c2-bce3641d2416.pdf",
            "news_date": "2022-01-31 15:23:32",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 29th October 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 29th October 2021 at 4.45 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ2(Jul-Sep)2021-22.pdf",
            "news_id": "86c68ad4-9a11-4086-b0f4-2b240f4984ec",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bfa36dca-488e-485b-a90e-0a6a85f2f066.pdf",
            "news_date": "2021-11-08 10:53:33",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 29th October 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 29th October 2021 at 4.45 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ2(Jul-Sep)2021-22.pdf",
            "news_id": "78351fc7-420d-4966-b5e6-af557e2ed1af",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8fdc2820-bdc0-415f-a78d-bcad7e96f930.pdf",
            "news_date": "2021-11-08 10:53:08",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 29Th October 2021",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 29th October 2021 at 4.45 p.m. has been uploaded on the Company's website and can be accessed through the link:<BR> <BR> http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ2(Jul-Sep)2021-22.mp3<BR> <BR> This is for your information and records please.",
            "news_id": "cdae5a9f-27bc-493b-9f45-6e1820cb881b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0faa0d09-cf55-4392-9d13-2761149f74f9.pdf",
            "news_date": "2021-10-29 18:57:09",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Dear Sir/Madam,<BR> Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 29th October 2021, approved the following:<BR> i. Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended 30th September 2021;<BR> ii. Payment of interim dividend of Rs. 9.50/- (475%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2021-22;<BR> iii. Fixed Wednesday, 10th November 2021 as the Record date for payment of interim dividend. lnterim dividend will be paid on or after Tuesday, 16th November 2021.<BR> <BR> Kindly note that the meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 2.15 p.m. and take the above on your records.<BR> <BR> Kindly take the above on your records.",
            "news_id": "f86bd655-3af7-4f4a-b433-1e12b427e8b5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55675dee-1db8-4743-a220-879eae3218a6.pdf",
            "news_date": "2021-10-29 14:29:05",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 30th July 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 29th July 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ1(Apr-Jun)2021-22.pdf<BR> <BR> This is for your information and records please.",
            "news_id": "2256ec28-a028-4d81-85df-8c2ef285d99d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3abeab2c-7c26-4694-8608-b8fd068f0f49.pdf",
            "news_date": "2021-08-02 18:48:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 29Th July 2021",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call  recording of the earnings call held on 29th July 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ1(Apr-Jun)2021-22.mp3<BR> <BR> Written transcript of the same will be submitted in due course.",
            "news_id": "33484759-1077-4817-aa47-f1fdb06fd064",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b210416-131a-4dd3-a46c-46c2eaba9ac8.pdf",
            "news_date": "2021-07-30 12:04:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting",
            "news_body": "At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter ended 30th June 2021;<BR> ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2021; <BR> iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2021;<BR> iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2021;<BR> v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2021;<BR> vi. Investors' presentation.",
            "news_id": "faea63c3-d60d-4449-9b28-8b774b988b26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7c3465f-8400-4a27-ba3b-738e4a418e4a.pdf",
            "news_date": "2021-07-29 16:01:12",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Schedule Of Earnings Conference Call Post Board Meeting",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements ) Regulations 2015, we are enclosing herewith the schedule of Earnings conference call to be<BR> held on 29th July 2021, post Board meeting.<BR> <BR> This is for your information and records please.",
            "news_id": "38d3e8d9-50ab-4876-9a87-3acb5ffc0922",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3721abd-ccb2-408e-b23c-1f5dc3f73af4.pdf",
            "news_date": "2021-07-22 17:50:57",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 30th April 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 30th April 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link http://ajantapharma.com/Results.aspx<BR> <BR> This is for your information and records please.",
            "news_id": "9a0f612a-1fc8-4524-8cb4-e70c5980ffa9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47d035f6-30eb-4976-907b-e1936e216dac.pdf",
            "news_date": "2021-05-04 14:24:30",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 30Th April 2021",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 30th April 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link http://ajantapharma.com/Results.aspx<BR> <BR> Written transcript of the same will be submitted in due course.<BR> <BR> This is for your information and records please.",
            "news_id": "be4d9011-da8b-44b4-b29b-230b98749a0e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b990fce-a821-4b29-9492-818f910aa45e.pdf",
            "news_date": "2021-04-30 20:30:55",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "<BR> Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> <BR> 1. Press Release;<BR> 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 4. Investor's presentation.<BR> <BR> Separate disclosure under Regulation 30 is being filed shortly. <BR> <BR> We shall inform in due course, date of the 42nd Annual General Meeting to be held for the year ended 31st March 2021. <BR> <BR> Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 4.00 p.m. <BR> <BR> Kindly take the above on your records.<BR>",
            "news_id": "e79a560b-5043-4f1b-81e3-cc262a74e801",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e474861e-b71c-45bc-8055-044da64de80d.pdf",
            "news_date": "2021-04-30 16:25:01",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting - Approve And Take On Record The Audited (Consolidated & Standalone) Financial Results Of The Company For The Quarter And Year Ended 31St March 2021",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> <BR> 1. Press Release;<BR> 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 4. Investor's presentation.<BR> <BR> Separate disclosure under Regulation 30 is being filed shortly. <BR> <BR> We shall inform in due course, date of the 42nd Annual General Meeting to be held for the year ended 31st March 2021. <BR> <BR> Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 4.00 p.m. <BR> <BR> Kindly take the above on your records.",
            "news_id": "88bb8263-73e8-4deb-a4c0-8e649ccaab42",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=816eb5c1-a96e-4f86-a9cd-a4382425e9ad.pdf",
            "news_date": "2021-04-30 16:09:17",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}